Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Balance Sheets

v2.4.0.8
Condensed Consolidated Balance Sheets (USD $)
In Thousands, unless otherwise specified
Sep. 30, 2013
Dec. 31, 2012
Current assets:    
Cash and cash equivalents $ 4,001 $ 11,029
Marketable securities 87,913 59,819
Collaboration receivable 5,545 15,635
Prepaid expenses and other current assets 1,819 1,167
Total current assets 99,278 87,650
Property and equipment, net 708 812
Other assets 1,059 1,059
Total assets 101,045 89,521
Current liabilities:    
Accounts payable 1,375 908
Accrued clinical and development expenses 8,291 5,750
Accrued liabilities 2,489 2,257
Deferred revenue, current 12,722 8,536
Total current liabilities 24,877 17,451
Warrant liability 23,790 32,558
Deferred revenue, non-current 69,628 53,097
Deferred rent 250 268
Total liabilities 118,545 103,374
Commitments and contingencies (Note 7)      
Stockholders' equity (deficit):    
Preferred stock, $0.001 par value, 2,000,000 shares authorized; no shares issued and outstanding      
Common stock, $0.001 par value, shares authorized: 150,000,000 shares; issued and outstanding: 59,174,123 shares at September 30, 2013 and 56,431,207 shares at December 31, 2012 59 56
Additional paid-in capital 326,492 309,343
Accumulated other comprehensive gain (loss) 38 11
Accumulated deficit (344,089) (323,263)
Total stockholders' equity (deficit) (17,500) (13,853)
Total liabilities and stockholders' equity (deficit) $ 101,045 $ 89,521